BeOne Medicines (BEIGF) Deferred Taxes (2017 - 2023)

BeOne Medicines (BEIGF) has reported Deferred Taxes for 7 consecutive years, with -$46000.0 the latest figure, recorded in Q4 2023.

• On a quarterly basis, Deferred Taxes fell 102.74% year-over-year to -$46000.0 in Q4 2023; TTM through Dec 2023 was $689000.0, a 66.54% decrease from a year earlier, with the FY2025 full-year figure at $9.5 million, down 63.56% from the prior year.
• Deferred Taxes was -$46000.0 for Q4 2023 at BeOne Medicines, down from $750000.0 in the prior quarter.
• Over five years, Deferred Taxes peaked at $14.8 million in Q3 2021 and troughed at -$12.3 million in Q1 2021.
• A 5-year average of -$142300.0 and a median of -$48500.0 in 2023 frame the typical range for Deferred Taxes.
• Across the five-year window, Deferred Taxes slumped 5847.09% in 2021 and soared 941.67% in 2022, its largest moves.
• Over 5 years, Deferred Taxes stood at $4.1 million in 2019, then jumped by 119.97% to $9.0 million in 2020, then tumbled by 89.99% to $903000.0 in 2021, then jumped by 85.94% to $1.7 million in 2022, then tumbled by 102.74% to -$46000.0 in 2023.
• The last three Deferred Taxes figures came in at -$46000.0 (Q4 2023), $750000.0 (Q3 2023), and -$51000.0 (Q2 2023), per Business Quant data.